(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Recommendations

Info

GBG-26 is the 1st randomised Phase III study to investigate continuation of Trastuzumab beyond progression Progression under Trastuzumab-based 1st-line therapy + taxane (n=114) or Progression under Herceptin monotherapy or non-taxane (n=42) Capecitabine 1,250 mg/m 2 bid d1-14 q21d + continuation of Trastuzumab 6 mg/kg q3w (n=78) Primary endpoint: Time to Progression R Capecitabine 1,250 mg/m 2 bid d1-14 q21d (n=78) von Minckwitz et al, J Clin Oncol 2009
GBG 26/BIG 03-05: main results Capecitabine Capecitabine Plus Trastuzumab Overall RR 27% 48.1% HR 2.50 (odds ratio) P Value .011 Median TTP 5.6 mo 8.2 mo 0.69 .034 Median OS 20.4 mo 25.5 0.76 .25 von Minckwitz et al, J Clin Oncol 2009
Page 1 and 2: Utilizzo dei farmaci nei diversi co
Page 3 and 4: HER2 positive breast cancer “Targ
Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
Page 9 and 10: Antibody-Dependent Cellular Cytotox
Page 11 and 12: Potenziale meccanismo di trastuzuma
Page 13: Malattia adiuvante
Page 17 and 18: DFS: Sequential (Arm B: AC → T
Page 19 and 20: Malattia Neo- adiuvante
Page 21 and 22: Studio NOAH: Event Free Survival ne
Page 23 and 24: Trastuzumab has transformed the pro
Page 25 and 26: Definition of resistance In most tu
Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
Page 29: Trastuzumab Capecitabine von Minckw
Page 33 and 34: Phase III, randomised, controlled s
Page 35 and 36: Lapatinib • Binds to intracellula
Page 37 and 38: Lapatinib may sensitise HER2 positi
Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
Page 41 and 42: HER2 dimerization is key to signali
Page 43 and 44: Trastuzumab binds to subdomain IV o
Page 45 and 46: Trastuzumab and pertuzumab may have
Page 47 and 48: Receptor-T-DM1 complex is internali

(.pdf) dr.ssa Antonella Ferro - Progettoeventi

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?